Parametric Portfolio Associates’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $49K | Sell |
504
-751
| -60% | -$96.4K | ﹤0.01% | 3633 |
|
|
2021
Q4 | $205K | Sell |
1,255
-3,299
| -72% | -$725K | ﹤0.01% | 3414 |
|
|
2021
Q3 | $1.24M | Buy |
4,554
+2,830
| +164% | +$865K | ﹤0.01% | 2695 |
|
|
2021
Q2 | $683K | Buy |
1,724
+873
| +103% | +$408K | ﹤0.01% | 2948 |
|
|
2021
Q1 | $460K | Buy |
851
+357
| +72% | +$222K | ﹤0.01% | 3539 |
|
|
2020
Q4 | $187K | Buy |
494
+230
| +87% | +$91.5K | ﹤0.01% | 3798 |
|
|
2020
Q3 | $100K | Sell |
264
-38
| -13% | -$16.8K | ﹤0.01% | 3796 |
|
|
2020
Q2 | $148K | Sell |
302
-47
| -13% | -$21K | ﹤0.01% | 3706 |
|
|
2020
Q1 | $128K | Buy |
349
+48
| +16% | +$24.8K | ﹤0.01% | 3673 |
|
|
2019
Q4 | $213K | Buy |
301
+52
| +21% | +$35.8K | ﹤0.01% | 3719 |
|
|
2019
Q3 | $160K | Buy |
249
+62
| +33% | +$49.2K | ﹤0.01% | 3758 |
|
|
2019
Q2 | $163K | Buy |
187
+18
| +11% | +$12.4K | ﹤0.01% | 3777 |
|
|
2019
Q1 | $97K | Sell |
169
-37
| -18% | -$15.5K | ﹤0.01% | 3822 |
|
|
2018
Q4 | $58K | Buy |
206
+65
| +46% | +$25.7K | ﹤0.01% | 3838 |
|
|
2018
Q3 | $68K | Sell |
141
-239
| -63% | -$102K | ﹤0.01% | 3889 |
|
|
2018
Q2 | $172K | Buy |
380
+52
| +16% | +$33K | ﹤0.01% | 3726 |
|
|
2018
Q1 | $193K | Sell |
328
-1,003
| -75% | -$625K | ﹤0.01% | 3769 |
|
|
2017
Q4 | $827K | Buy |
1,331
+761
| +134% | +$547K | ﹤0.01% | 3110 |
|
|
2017
Q3 | $525K | Sell |
570
-1
| -0.2% | -$888 | ﹤0.01% | 3397 |
|
|
2017
Q2 | $533K | Buy |
571
+31
| +6% | +$30.4K | ﹤0.01% | 3336 |
|
|
2017
Q1 | $514K | Buy |
540
+413
| +325% | +$385K | ﹤0.01% | 3193 |
|
|
2016
Q4 | $102K | Buy |
127
+3
| +2% | +$2.7K | ﹤0.01% | 3705 |
|
|
2016
Q3 | $105K | Sell |
124
-529
| -81% | -$425K | ﹤0.01% | 3674 |
|
|
2016
Q2 | $538K | Buy |
653
+499
| +324% | +$543K | ﹤0.01% | 3149 |
|
|
2016
Q1 | $171K | Buy |
154
+13
| +9% | +$13.3K | ﹤0.01% | 3779 |
|
|
2015
Q4 | $176K | Sell |
141
-19
| -12% | -$31.4K | ﹤0.01% | 3762 |
|
|
2015
Q3 | $217K | Buy |
160
+17
| +12% | +$28.1K | ﹤0.01% | 3064 |
|
|
2015
Q2 | $257K | Sell |
143
-292
| -67% | -$453K | ﹤0.01% | 3651 |
|
|
2015
Q1 | $703K | Sell |
435
-121
| -22% | -$179K | ﹤0.01% | 3048 |
|
|
2014
Q4 | $423K | Buy |
556
+2
| +0.4% | +$1.06K | ﹤0.01% | 3358 |
|
|
2014
Q3 | $219K | Sell |
554
-27
| -5% | -$13K | ﹤0.01% | 3585 |
|
|
2014
Q2 | $352K | Sell |
581
-602
| -51% | -$335K | ﹤0.01% | 3425 |
|
|
2014
Q1 | $813K | Buy |
1,183
+321
| +37% | +$215K | ﹤0.01% | 2834 |
|
|
2013
Q4 | $561K | Buy |
862
+356
| +70% | +$212K | ﹤0.01% | 3089 |
|
|
2013
Q3 | $299K | Buy |
506
+238
| +89% | +$107K | ﹤0.01% | 3396 |
|
|
2013
Q2 | $85K | Buy |
+268
| New | +$74.4K | ﹤0.01% | 3609 |
|
Other funds holding TCRT
MP
DCM
N
Parametric Portfolio Associates's TCRT Position: Q1 2022 in Review
Parametric Portfolio Associates reduced its Alaunos Therapeutics (TCRT) stake by 60% in Q1 2022, selling an estimated $96.4K and leaving 504 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #3633.
Parametric Portfolio Associates first reported a position in TCRT in Q2 2013 and has held it in 36 quarters since. The position peaked at $1.24M in Q3 2021. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.
- Parametric Portfolio Associates held 504 shares of Alaunos Therapeutics worth $49K as of Q1 2022.
- Parametric Portfolio Associates sold 751 Alaunos Therapeutics shares in Q1 2022, an estimated $96.4K.
- Alaunos Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3633 holding.
- Parametric Portfolio Associates first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 36 quarters since.
- Parametric Portfolio Associates's Alaunos Therapeutics position peaked at $1.24M in Q3 2021.
- 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.
Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.